 |
2016-01-29 02:19:52 Could you send me an ●●●●●●ation form? ●●●●●● yyen The mood may be merry – the ●●●●●●ce ●●●●●●d ●●●●●●y – but ●●●●●●sive too. As so often, B●●●●●●, the ●●●●●●’s boy who ●●●●●● to ●●●●●● up and get away, is ●●●●●●ying ●●●●●●s of ●●●●●●f in his ●●●●●●onist. ●●●●●● ●●●●●●cy in ●●●●●●er ●●●●●●gton ODYSSEY MONO (N=103) was a ●●●●●●ized, ●●●●●●-blind, ●●●●●●-●●●●●●lled, ●●●●●●el-group study to ●●●●●●te the ●●●●●●cy and ●●●●●● of ●●●●●●umab over 24 weeks in ●●●●●●ts with ●●●●●●y ●●●●●●●●●●●●●●●●●●ia and ●●●●●●te ●●●●●●●●●●●●ar risk. P●●●●●●s in the trial were ●●●●●●ized to ●●●●●●e ●●●●●●erapy with ●●●●●● ●●●●●●ibe 10 mg, an ●●●●●●ative to ●●●●●● ●●●●●●y, or ●●●●●●umab. A●●●●●●mab was self-●●●●●●●●●●●● ●●●●●●lly at its low dose of 75 mg every two weeks, and was up-●●●●●●ed at week 12 to 150 mg if the LDL-C ●●●●●●ement at week 8 was above 70 mgdL. The ●●●●●●ty of ●●●●●●umab ●●●●●●ts in the trial ●●●●●●ed on the ●●●●●●l low dose of ●●●●●●umab ●●●●●●e they ●●●●●●ed LDL-C below 70 mgdL at week 8. A●●●●●●mab was self-●●●●●●●●●●●● ●●●●●●●●●●●●ly using a ●●●●●● 1 ●●●●●●iter (mL) auto-●●●●●●or. |